.RESEARCH STUDY HIGHLIGHT.16 October 2024.
In the NIAGARA hearing, the addition of perioperative durvalumab to typical treatment for muscle-invasive sac cancer cells improved event-free as well as generally survival, noting a new procedure possibility for this problem.